Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05REB
|
||||
| Former ID |
DIB005851
|
||||
| Drug Name |
ZT-1
|
||||
| Synonyms |
(5R,9R)-5-(5-Chloro-2-hydroxy-3-methoxybenzylideneamino)-11-ethylidene-7-methyl-1,2,5,6,9,10-hexahydro-5,9-methanocycloocta[b]pyridin-2-one; 180694-97-7
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H23ClN2O3
|
||||
| Canonical SMILES |
CC=C1C2CC3=C(C1(CC(=C2)C)NC=C4C=C(C=C(C4=O)OC)Cl)C=CC(=<br />O)N3
|
||||
| InChI |
1S/C23H23ClN2O3/c1-4-17-14-7-13(2)11-23(17,18-5-6-21(27)26-19(18)9-14)25-12-15-8-16(24)10-20(29-3)22(15)28/h4-8,10,12,14,25H,9,11H2,1-3H3,(H,26,27)/b15-12-,17-4+
|
||||
| InChIKey |
GYTJFKCCTYZWGL-WQOXWKGMSA-N
|
||||
| CAS Number |
CAS 180694-97-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Acetylcholinesterase | Target Info | Inhibitor | [2], [3] | |
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Cholinergic synapse | |||||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Pathway Interaction Database | ATF-2 transcription factor network | ||||
| PathWhiz Pathway | Phospholipid Biosynthesis | ||||
| WikiPathways | Monoamine Transport | ||||
| Biogenic Amine Synthesis | |||||
| Acetylcholine Synthesis | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| References | |||||
| REF 1 | Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. Acta Pharmacol Sin. 2013 Jul;34(7):976-82. | ||||
| REF 2 | A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651-6. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.